Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Phio Pharmaceuticals Corp.PHIO · Entity 7889 | Director | February 05, 2026 | February 06, 2026 |
| Xenetic Biosciences, Inc.XBIO · Entity 8008 | Chief Sciencific Officer | December 11, 2023 | December 13, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Phio Pharmaceuticals Corp.
Report date February 05, 2026 · Filed February 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.0001 par valueSEC Table I · non-derivative | Direct | 35,155 |
Reported balance
After 2026-02-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-05 · Grant · Acquired 16,600 · Balance 35,155 F1: Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant. F2: Includes shares of common stock underlying unvested restricted stock units. F3: The number of reported securities has been adjusted to reflect prior reverse stock splits. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant.
F2: Includes shares of common stock underlying unvested restricted stock units.
F3: The number of reported securities has been adjusted to reflect prior reverse stock splits.
Xenetic Biosciences, Inc.
Report date December 11, 2023 · Filed December 13, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.88 · Expires 2033-12-11 | Direct | 10,000 |
Reported balance
After 2023-12-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-12-11 · Grant · Acquired 10,000 · Balance 10,000 F1: The shares underlying the options will vest and become exercisable as follows: one-third of the shares shall vest on the first anniversary of December 11, 2023; the remaining two-thirds of the shares shall vest in eight equal quarterly installments commencing on March 11, 2025 and ending on December 11, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the options will vest and become exercisable as follows: one-third of the shares shall vest on the first anniversary of December 11, 2023; the remaining two-thirds of the shares shall vest in eight equal quarterly installments commencing on March 11, 2025 and ending on December 11, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 05, 2026 Filed Feb 6, 2026 08:01 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon Stock, $.0001 par value | 16,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-26-000813 · ownership.xml · nonDerivative · entry 1 Lockshin Curtis · CIK 0001383556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,155 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. F3 · balance_after: The number of reported securities has been adjusted to reflect prior reverse stock splits. Read SEC document |
| September 11, 2025 Filed Sep 15, 2025 08:29 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon Stock, $.0001 par value | 16,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-25-006959 · ownership.xml · nonDerivative · entry 1 Lockshin Curtis · CIK 0001383556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,555 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. F3 · balance_after: The number of reported securities has been adjusted to reflect prior reverse stock splits. Read SEC document |
| September 11, 2024 Filed Sep 12, 2024 16:11 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon Stock, $0.0001 par value | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-24-006336 · ownership.xml · nonDerivative · entry 1 Lockshin Curtis · CIK 0001383556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest on the first anniversary of the grant. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| December 11, 2023 Filed Dec 13, 2023 17:30 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Options · Derivative | 10,000 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0001683168-23-008825 · ownership.xml · derivative · entry 1 Lockshin Curtis · CIK 0001383556 · Chief Sciencific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-12-11 F1 · derivative.exercise_date: The shares underlying the options will vest and become exercisable as follows: one-third of the shares shall vest on the first anniversary of December 11, 2023; the remaining two-thirds of the shares shall vest in eight equal quarterly installments commencing on March 11, 2025 and ending on December 11, 2026. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 19:30 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock, $0.0001 par value | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011942 · doc4.xml · nonDerivative · entry 1 Lockshin Curtis · CIK 0001383556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,197 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Effective as of 12:01 a.m. Eastern Time on January 26, 2023, the issuer effected a reverse split of its outstanding shares of common stock at a ratio of 1-for-12. Read SEC document |
| March 24, 2022 Filed Mar 28, 2022 17:13 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Options · Derivative | 50,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001683168-22-002001 · ownership.xml · derivative · entry 1 Lockshin Curtis · CIK 0001383556 · Chief Sciencific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-03-24 F1 · derivative.exercise_date: The shares underlying the options will vest and become exercisable as follows: one-third of the shares shall vest on the first anniversary of March 24, 2022; the remaining two-thirds of the shares shall vest in eight equal quarterly installments commencing on June 24, 2023 and ending on March 24, 2025. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 20:12 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock, $0.0001 par value | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-010405 · doc4.xml · nonDerivative · entry 1 Lockshin Curtis · CIK 0001383556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,366 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| March 18, 2021 Filed Mar 22, 2021 17:30 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Options · Derivative | 50,000 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001683168-21-001020 · ownership.xml · derivative · entry 1 Lockshin Curtis · CIK 0001383556 · Chief Sciencific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-03-18 F1 · derivative.exercise_date: The shares underlying the options will vest and become exercisable as follows: one-third of the shares shall vest on the first anniversary of March 18, 2021; the remaining two-thirds of the shares shall vest in eight equal quarterly installments commencing on June 18, 2022 and ending on March 18, 2024. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:05 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock, $0.0001 par value | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017571 · doc4.xml · nonDerivative · entry 1 Lockshin Curtis · CIK 0001383556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,366 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. F2 · balance_after: Effective as of 12:01 a.m. Eastern Time on January 15, 2020, the issuer effected a reverse split of its outstanding shares of common stock at a ratio of 1-for-55. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 18:37 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Options · Derivative | 90,000 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0001683168-19-003919 · ownership.xml · derivative · entry 1 Lockshin Curtis · CIK 0001383556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2029-12-04 F1 · derivative.exercise_date: The shares underlying the options will vest and become exercisable as follows: 30,000 shares shall vest on the first anniversary of December 4, 2019 ("Vesting Start Date"); 30,000 shares shall vest on the second anniversary of the Vesting Start Date; and 30,000 shares shall vest on the third anniversary of the Vesting Start Date. Read SEC document |
| February 13, 2019 Filed Feb 15, 2019 21:09 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-010828 · doc4.xml · nonDerivative · entry 1 Lockshin Curtis · CIK 0001383556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,130 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 21:37 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-045461 · doc4.xml · nonDerivative · entry 1 Lockshin Curtis · CIK 0001383556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,130 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 17:24 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | GrantStock option (right to buy) · Derivative | 2,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001209191-17-007746 · doc4.xml · derivative · entry 1 Lockshin Curtis · CIK 0001383556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2027-02-01 F1 · derivative.exercise_date: The stock option vests in equal quarterly installments over one year beginning on the first quarterly anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.